InClinica, formerly IndiPharm, is a global clinical CRO that specializes in leading companies through clinical trials, and works across all phases of clinical development, with a particular strength in assisting small to mid-sized companies.
Latest InClinica News
Oct 27, 2016
> InClinica and IC LifeSciences Launch Regional Office in Malaysia × InClinica and IC LifeSciences Launch Regional Office in Malaysia 2016-10-27 08:00 -Clinical Research Organisation (CRO) targets rapid development of clinical research studies in the Asia Pacific region KUALA LUMPUR, Malaysia, Oct. 27, 2016 /PRNewswire/ -- InClinica, a contract Clinical Research Organisation (CRO) headquartered in Philadelphia, USA and its subsidiary company, IC LifeSciences launched their Asia Pacific office in Kuala Lumpur recently. The regional office located at Menara KH will serve as a hub for clinical research and life science business development in the Asia Pacific region. From left: Prof. Paul Zimmet, Professor of Diabetes, Monash University; Jeffrey Scott Yablon, Vice President and General Manager, InClinica; Prof. Tan Sri Dato’ Seri Dr. Hj. Mohd. Ismail Merican, Pro-Chancellor and Chairman, MAHSA University; and Datuk Dr. Rahman Ismail, Consulting Medical Director, InClinica. InClinica and IC LifeSciences provide an extensive range of clinical and non-clinical research services through partnerships with both local and international organisations in the pharmaceutical and biotechnology industry. Malaysia is chosen as their regional hub because of its conducive environment for research and life science advancements, apart from its ease of connectivity to the other nations in Asia Pacific. The evening commenced with a warm welcome from Jeffrey S. Yablon, Executive Vice President of InClinica and IC LifeSciences, followed by opening remarks by Tan Sri Dato' Seri Dr. Hj. Mohd. Ismail Merican, Pro-Chancellor and Chairman of MAHSA University. About 40 guests from the research industry and academia were present to mark the occasion. "Today's launch represents our continued growth and commitment to building a sustainable and growing organisation in the region," said Jeff Yablon. "By setting up base in Malaysia, we believe we will be able to advance the clinical research landscape via knowledge transfer and sharing. We are excited about the massive potential in the Asia Pacific region which remains untapped, and look forward to rapid progress within the next three years. " "Non-communicable diseases such as diabetes, hypertension, and obesity are rising at alarming rates in this part of the world due to industrialisation and fast-paced lifestyles. As such, clinical research is a vital aspect of medical advancement to combat these diseases and others such as infectious diseases," said Tan Sri Dr. Ismail. "We are pleased that InClinica has chosen Malaysia as its regional base, which will put us first in line in the discovery of innovative medical advancements. " InClinica also has offices in the United Kingdom, Australia and Greece. The management team boasts over 100 years of combined experience in drug and device development across diverse therapeutic areas. Through IC LifeSciences, InClinica will be collaborating with MyBioScienceLab in Malacca, which provides chemical and biological analysis for food, pharmaceuticals, nutraceuticals, medical devices and cosmetics. About InClinica ( www.inclinica.com ) InClinica, headquartered in Philadelphia, USA, is a global clinical contract research organization that works on all phases of clinical development. The company was established in 2016 following the acquisition of an existing global CRO by private equity firm, Velocity Fund Partners. InClinica is spearheaded by a management team with over 100 years of combined experience in drug and device development across diverse therapeutic areas. In addition to the U.S. and Malaysia, InClinica also has offices in the U.K., Australia, and Greece. About IC LifeSciences IC LifeSciences is a subsidiary company targeting global business development opportunities in the healthcare and life science industry. Founded in 2016, IC LifeSciences offers innovative science-driven products and services in multiple therapeutic areas. Currently, IC LifeSciences collaborates with testing facilities, MyBioScienceLab (Malacca) and Gateway Analytical (Pittsburgh, Pennsylvania), to provide chemical and biological analysis for food, pharmaceuticals, nutraceuticals, medical devices, and cosmetics.
InClinica Frequently Asked Questions (FAQ)
Where is InClinica's headquarters?
InClinica's headquarters is located at 701 Lee Road, Wayne.
What is InClinica's latest funding round?
InClinica's latest funding round is Unattributed - IV.
How much did InClinica raise?
InClinica raised a total of $5.57M.
Who are the investors of InClinica?
Investors of InClinica include Velocity Fund Partners.
Who are InClinica's competitors?
Competitors of InClinica include EUSA Pharma, Deciphera Pharmaceuticals, Nutrinia, Vistagen, GC-Rise Pharmaceutical and 7 more.
Compare InClinica to Competitors
Intarcia Therapeutics operates as a biopharmaceutical company. The company develops and commercializes therapies to transform the prevention and management of chronic diseases. The company was founded in 1995 and is based in Boston, Massachusetts.
Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.
PhytoCeutica is a clinical-stage biopharmaceutical company that operates in the healthcare and pharmaceutical industry. The company's main focus is on developing prescription drugs intended for the treatment of cancer and other life-threatening diseases, with the aim of improving survival time and quality of life. It was founded in 1998 and is based in New Haven, Connecticut.
Indena is a company dedicated to the identification, development and production of active principles derived from plants, for use in the pharmaceutical, health-food and cosmetics industries. Indena, a privately owned Italian company, has around 700 employees, including 10% dedicated to full-time research, aims to manage cultivation, manufacturing, and distribution operations in more than 40 countries throughout the world. The key to Indena's success is its research, covering: the screening of medicinal plants for their pharmacological benefits; the identification of new active principles; and the development of extraction and purification systems at the cutting-edge of industrial application. The phyto-chemical research is carried out in Indena's own Research Center in Settala, Italy. Indena also co-operates with the world's most prestigious universities and private research institutions in the biological assessment of safety and effectiveness up to clinical phase I. One of the main strategic objectives of the research is the development of new active principles for pharmaceutical applications. This is also an indispensable base for the health-food and cosmetics industries. In the pharmaceutical sector Indena is currently focusing on the development of anti-cancer treatments, following the successes of paclitaxel, as well as on anti-microbial and on anti-viral drugs. Also under study are active principles for the treatment of pathologies and dysfunction of the central nervous system, such as depression, anxiety, impotence, sleep disorders, and algesia. Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.
Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.
Led by a team with vast experience in pharmaceuticals, ophthalmology and start-ups, Chakshu Research is committed to develop pharmaceutical treatments for degenerative ocular diseases. The company are developing a self-administered eyedrop to reduce and repair oxidative damage which has been implicated in blinding degenerative diseases. While the company's drug platform is being tested on the company's lead indication, cataract; the company are also in clinical trials for glaucoma and asteroid hyalosis.